Back HIV Populations Women & HIV

Women & HIV

IAS 2015: WAVES Shows Elvitegravir Regimen Beats Boosted Atazanavir for Women with HIV

A study of antiretroviral treatment specifically for women with HIV showed that a single-tablet regimen containing the integrase inhibitor elvitegravir suppressed the virus better than a regimen containing ritonavir-boosted atazanavir, according to a poster presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver. This study is important in part because it demonstrates that including more women in clinical trials is feasible.

alt

Read more:

CROI 2015: Levonorgestrel Contraception May Be Less Effective for Women Taking Efavirenz

African women who took efavirenz as part of a combination antiretroviral regimen were more likely to become pregnant while using the levonorgestrel implant, likely due to a drug interaction that lowers levels of the hormonal contraceptive, according to a presentation at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

alt

Read more:

Meta-Analysis Shows Injectable Hormonal Contraception Linked to HIV Infection Risk

Women who use the long-acting injectable contraceptive Depo-Provera had a modest but significant increase in the risk of contracting HIV infection, according to a meta-analysis of 12 studies published in the January 8Lancet Infectious Diseases. However, there was no increase in risk for women using birth control pills.

alt

Read more:

March 10 Is National Women and Girls HIV/AIDS Awareness Day

Tuesday, March 10, is National Women and Girls HIV/AIDS Awareness Day (NWGHAAD), an annual opportunity to call attention to the impact of HIV and AIDS on women and girls worldwide.

alt

Read more:

AIDS 2014: More Data Suggest Increased HIV Risk from Injectable Contraceptives

A sophisticated meta-analysis, pooling individual-level data on 37,000 women, has found that the use of DMPA injectable hormonal contraception is linked with a higher rate of new HIV infections among women, researchers reported at the 20th International AIDS Conference last week in Melbourne. However, the World Health Organization (WHO) announced at the same session that its guideline supporting the provision of this contraceptive to women at risk of HIV infection remains unchanged.

alt

Read more: